The entourage effect is a name given to a biological and consumption process that allows the largest, widest range of medicinal benefits to be felt from consuming cannabis. Smoking or vaporizing raw bud allows all 113 phytocannabinoids and 455+ terpenes to be absorbed, instead of just a singular phytocannabinoid like THC or CBD that you would get from concentrates. The more phytocannabinoids and the more terpenes that are consumed, the better for you it will be.
Examples of this effect can be seen in even minor comparisons between a few chemicals found in cannabis. Mangoes are high in the terpene myrcene, which has a synergistic effect on THC that intensifies the high. Consuming a mango before consuming cannabis can make the high last longer and hit harder. Alternatively, caryophyllene has the opposite effect, and can reduce the intensity of a high by interacting directly with the THC. Linalool has been shown to augment the anti-seizure effects of CBD and other phytocannabinoids, myrcene has been shown to influence CBG’s anticancer properties and caryophyllene has been shown to interact with CBD in its CB2 receptor binding, among many other interactions.
A possible reason for smoking cannabis, the “archaic” form of consumption, remaining so popular is thanks to the entourage effect. Cannabis and all of its phytocannabinoids, when combined with the terpenes naturally found in the bud, were found to have 330% more activity than THC alone. A combination of them is rare, if existing at all in the concentration world. Some oil making companies will reinject terpenes back into their products, but it pales in comparison to the raw bud.
- Ben-Shabat, S. Fride, E. Sheskin, T. Tamiri, T. Rhee, MH. Vogel, Z. Bisogno, T. De Petrocellis, L. Di Marzo, V. Mechoulam, R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology. (1998)
- Mechoulam, R. Ben-Shabat, S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Natural Product Reports. (1999)
- McPartland, JM. Russo, EB. Cannabis and cannabis extracts: greater than the sum of their parts? Journal of Cannabis Therapeutics. (2001)
- Whittle, BA. Guy, GW. Robson, P. Prospects for new cannabis-based prescription medicines. Journal of Cannabis Therapeutics. (2001)
- Williamson, EM. Synergy and other interactions in phytomedicines. Phytomedicine. (2001)
- Wilkinson, JD. Whalley, BJ. Baker, D. Pryce, G. Constanti, A. Gibbons, S. Williamson, EM. Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? Journal of Pharmaceutical Pharmacology. (2003)
- Russo, EB. Guy, GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses. (2006)
- Russo, EB. Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. British Journal of Pharmacology. (2011)
- McPartland, JM. Russo, EB. Pertwee, RG. Non-phytocannabinoid constituents of cannabis and herbal synergy. Handbook of Cannabis. Oxford University Press. (2014)
- Russo, EB. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Frontiers in Pharmacology. (2016)
- Piomelli, D. Russo, EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. (2016)
- Blasco-Benito, S. Seijo-Vila, M. Caro-Villalobos, M. Tundidor, I. Andradas, C. Garcia-Taboada, E. Wade, J. Smith, S. Guzman, M. Perez-Gomez, E. Gordon, M. Sanchez, C. Appraising the “Entourage Effect”: Antitumor Action of a pure Cannabinoid versus a Botanical Drug Preparation in Preclinical Models of Breast Cancer. Biochem Pharmacology. (2018)
- Seshata. Understanding Terpenes. Green Flower. (2018)
- Ross, M. Peters, J. Ideal Dosing. Green Flower. (2018)